bortezomib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
proteasome inhibitors 391 179324-69-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • LDP-341
  • PS-341
  • bortezomib
  • velcade
  • radiciol
A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.
  • Molecular weight: 384.24
  • Formula: C19H25BN4O4
  • CLOGP: 0.78
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 124.44
  • ALOGS: -3.86
  • ROTB: 9

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 3.30 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.08 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 19 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.17 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 18 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 14, 2019 EMA FRESENIUS KABI DEUTSCHLAND GMBH
Aug. 22, 2019 PMDA Janssen Pharmaceutical K.K.
May 13, 2003 FDA MILLENNIUM PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Plasma cell myeloma 5177.58 13.26 1959 57694 45915 53243498
Neuropathy peripheral 2203.62 13.26 1392 58261 101795 53187618
Thrombocytopenia 506.39 13.26 696 58957 138031 53151382
Plasma cell myeloma recurrent 503.00 13.26 167 59486 2590 53286823
Platelet count decreased 390.64 13.26 540 59113 107559 53181854
Diarrhoea 342.32 13.26 1491 58162 624055 52665358
Disease progression 341.30 13.26 491 59162 101429 53187984
Rheumatoid arthritis 335.43 13.26 3 59650 314528 52974885
Plasmacytoma 330.32 13.26 120 59533 2461 53286952
Constipation 232.14 13.26 612 59041 197800 53091613
Pneumonia 230.47 13.26 982 58671 406187 52883226
Plasma cell leukaemia 226.15 13.26 75 59578 1158 53288255
Neutropenia 212.16 13.26 516 59137 158669 53130744
Polyneuropathy 210.07 13.26 149 59504 13084 53276329
White blood cell count decreased 198.34 13.26 433 59220 124042 53165371
Pancytopenia 160.63 13.26 330 59323 90598 53198815
Drug hypersensitivity 159.88 13.26 49 59604 265193 53024220
Maternal exposure during pregnancy 155.18 13.26 4 59649 155635 53133778
Headache 150.78 13.26 230 59423 536591 52752822
Full blood count decreased 145.40 13.26 156 59497 23873 53265540
Tumour lysis syndrome 142.22 13.26 96 59557 7778 53281635
Contraindicated product administered 133.30 13.26 4 59649 135625 53153788
Arthralgia 130.66 13.26 181 59472 439602 52849811
Exposure during pregnancy 125.25 13.26 3 59650 124857 53164556
Sepsis 124.20 13.26 403 59250 146026 53143387
Drug ineffective 114.98 13.26 498 59155 816747 52472666
Unevaluable event 113.75 13.26 201 59452 49297 53240116
Laboratory test abnormal 113.04 13.26 138 59515 24271 53265142
Peripheral sensory neuropathy 110.02 13.26 79 59574 7069 53282344
Amyloidosis 109.37 13.26 43 59610 1103 53288310
Febrile neutropenia 104.95 13.26 306 59347 104630 53184783
Anaemia 103.50 13.26 594 59059 276124 53013289
Neutrophil count decreased 103.44 13.26 192 59461 48906 53240507
Cardiac amyloidosis 101.92 13.26 36 59617 678 53288735
Product use in unapproved indication 100.60 13.26 315 59338 111974 53177439
Pain 97.02 13.26 336 59317 588062 52701351
Dehydration 96.17 13.26 408 59245 168002 53121411
Glossodynia 91.69 13.26 5 59648 100286 53189127
Deep vein thrombosis 90.91 13.26 250 59403 82663 53206750
Septic shock 86.24 13.26 205 59448 62024 53227389
Drug interaction 85.26 13.26 72 59581 219257 53070156
Posterior reversible encephalopathy syndrome 82.45 13.26 96 59557 16064 53273349
Hordeolum 80.90 13.26 44 59609 2407 53287006
Chalazion 80.77 13.26 25 59628 305 53289108
Light chain analysis increased 78.02 13.26 34 59619 1138 53288275
Therapeutic product effect decreased 77.83 13.26 22 59631 125633 53163780
Off label use 77.43 13.26 837 58816 471375 52818038
Condition aggravated 75.09 13.26 136 59517 296998 52992415
Overdose 74.31 13.26 15 59638 107721 53181692
Herpes zoster 73.16 13.26 215 59438 73804 53215609
Swelling 72.72 13.26 64 59589 191041 53098372
Orthostatic hypotension 71.17 13.26 123 59530 29630 53259783
Primary amyloidosis 69.24 13.26 15 59638 34 53289379
Cytopenia 69.04 13.26 67 59586 9103 53280310
Renal failure 66.04 13.26 285 59368 118167 53171246
Musculoskeletal stiffness 65.40 13.26 28 59625 123340 53166073
Hyperviscosity syndrome 65.26 13.26 19 59634 185 53289228
Alopecia 65.13 13.26 101 59552 234482 53054931
Abdominal discomfort 64.46 13.26 92 59561 220970 53068443
Protein total increased 62.03 13.26 38 59615 2604 53286809
Monoclonal immunoglobulin present 61.98 13.26 26 59627 791 53288622
Myelodysplastic syndrome 61.18 13.26 84 59569 16576 53272837
Discomfort 60.46 13.26 16 59637 95456 53193957
Injection site pain 58.11 13.26 27 59626 113364 53176049
Arthropathy 57.98 13.26 44 59609 141409 53148004
Thrombosis 56.67 13.26 173 59480 60620 53228793
Stem cell transplant 55.07 13.26 31 59622 1814 53287599
Wound 54.91 13.26 17 59636 91540 53197873
Joint swelling 54.37 13.26 113 59540 234525 53054888
Haemoglobin decreased 53.34 13.26 298 59355 137009 53152404
Cytomegalovirus infection reactivation 53.21 13.26 34 59619 2510 53286903
Coombs indirect test positive 52.97 13.26 12 59641 36 53289377
Haematotoxicity 52.63 13.26 54 59599 7843 53281570
Treatment failure 52.55 13.26 40 59613 128363 53161050
Therapy partial responder 52.07 13.26 48 59605 6115 53283298
Wrong technique in product usage process 51.88 13.26 4 59649 60028 53229385
Atrial fibrillation 51.39 13.26 254 59399 111398 53178015
Pericarditis 51.14 13.26 6 59647 64400 53225013
Pathological fracture 49.73 13.26 54 59599 8370 53281043
Drug abuse 45.43 13.26 9 59644 65517 53223896
Suicide attempt 44.77 13.26 6 59647 58162 53231251
Autonomic neuropathy 44.50 13.26 22 59631 986 53288427
Mobility decreased 44.26 13.26 15 59638 76256 53213157
Hypocalcaemia 43.19 13.26 99 59554 29238 53260175
Hepatic enzyme increased 42.51 13.26 47 59606 126148 53163265
Hypercalcaemia 42.50 13.26 88 59565 24260 53265153
Ageusia 42.45 13.26 61 59592 12553 53276860
Body dysmorphic disorder 41.81 13.26 14 59639 223 53289190
Bone marrow failure 41.47 13.26 99 59554 30016 53259397
Pyrexia 41.23 13.26 656 58997 402537 52886876
Ileus paralytic 41.08 13.26 37 59616 4574 53284839
Cytomegalovirus infection 40.62 13.26 76 59577 19463 53269950
Malignant neoplasm progression 40.51 13.26 173 59480 71368 53218045
Hypersensitivity 40.42 13.26 112 59541 210553 53078860
Mesenteric abscess 40.26 13.26 11 59642 83 53289330
Anxiety 38.92 13.26 103 59550 196601 53092812
Bone pain 38.84 13.26 135 59518 50587 53238826
Therapy non-responder 38.72 13.26 132 59521 48988 53240425
Depression 38.42 13.26 93 59560 182959 53106454
Migraine 38.42 13.26 21 59632 80396 53209017
Peripheral sensorimotor neuropathy 38.08 13.26 22 59631 1353 53288060
Fibromyalgia 37.90 13.26 3 59650 44072 53245341
Peripheral motor neuropathy 37.65 13.26 23 59630 1568 53287845
Large intestinal ulcer perforation 37.64 13.26 10 59643 67 53289346
Blood pressure increased 37.52 13.26 62 59591 140417 53148996
Hepatitis B reactivation 37.50 13.26 25 59628 1983 53287430
Endocarditis bacterial 37.47 13.26 17 59636 627 53288786
Pneumonia fungal 36.91 13.26 35 59618 4621 53284792
Plasmablastic lymphoma 36.65 13.26 13 59640 248 53289165
Colitis 35.73 13.26 115 59538 41437 53247976
Electrolyte imbalance 35.03 13.26 70 59583 18814 53270599
Pleural effusion 34.87 13.26 193 59460 88386 53201027
Blood potassium decreased 34.81 13.26 112 59541 40348 53249065
Nasal abscess 34.76 13.26 11 59642 145 53289268
Crossmatch incompatible 33.74 13.26 8 59645 31 53289382
Fatigue 33.56 13.26 1060 58593 729446 52559967
Hypoaesthesia 32.96 13.26 258 59395 132737 53156676
Oedema peripheral 32.75 13.26 313 59340 170474 53118939
Syncope 32.75 13.26 226 59427 111767 53177646
Gastrointestinal fungal infection 32.15 13.26 12 59641 266 53289147
Hypertension 31.65 13.26 137 59516 225294 53064119
Inappropriate antidiuretic hormone secretion 30.88 13.26 58 59595 14893 53274520
Adverse drug reaction 30.60 13.26 130 59523 53495 53235918
Taste disorder 30.50 13.26 41 59612 7927 53281486
Renal amyloidosis 30.42 13.26 10 59643 150 53289263
Osteolysis 30.19 13.26 25 59628 2760 53286653
Suicidal ideation 30.09 13.26 15 59638 60496 53228917
Target skin lesion 29.68 13.26 9 59644 102 53289311
Morganella infection 29.57 13.26 14 59639 570 53288843
Blood stem cell harvest failure 29.44 13.26 8 59645 59 53289354
Palpitations 29.39 13.26 43 59610 102305 53187108
Blister 29.17 13.26 27 59626 78726 53210687
Rash 28.83 13.26 677 58976 445514 52843899
Large intestine perforation 28.81 13.26 40 59613 7974 53281439
Osteoarthritis 28.77 13.26 22 59631 70464 53218949
Mantle cell lymphoma 28.64 13.26 14 59639 612 53288801
Asthenia 28.23 13.26 540 59113 343050 52946363
Anaphylactic reaction 28.19 13.26 15 59638 58311 53231102
Clostridium bacteraemia 28.03 13.26 10 59643 194 53289219
Bronchiolitis 27.95 13.26 23 59630 2517 53286896
Disturbance in social behaviour 27.86 13.26 24 59629 2797 53286616
Helicobacter infection 27.86 13.26 5 59648 39064 53250349
Acute lymphocytic leukaemia 27.54 13.26 24 59629 2841 53286572
Guillain-Barre syndrome 27.33 13.26 27 59626 3748 53285665
Refractory cytopenia with multilineage dysplasia 27.01 13.26 9 59644 141 53289272
Joint ankylosis 26.86 13.26 14 59639 702 53288711
Sinus polyp 26.84 13.26 11 59642 315 53289098
Spinal cord compression 26.63 13.26 27 59626 3867 53285546
Blood pressure fluctuation 26.50 13.26 4 59649 35466 53253947
Inappropriate schedule of product administration 26.20 13.26 27 59626 74851 53214562
Bone lesion 26.08 13.26 32 59621 5654 53283759
Product quality issue 25.84 13.26 5 59648 37018 53252395
Arthritis 25.74 13.26 36 59617 87262 53202151
COVID-19 25.53 13.26 95 59558 36793 53252620
Adenoviral haemorrhagic cystitis 25.45 13.26 9 59644 170 53289243
Pseudomonal sepsis 24.54 13.26 20 59633 2159 53287254
Stress 24.36 13.26 17 59636 57067 53232346
Heart rate increased 24.21 13.26 34 59619 82281 53207132
Blood lactate dehydrogenase increased 24.17 13.26 66 59587 21715 53267698
Flushing 24.09 13.26 26 59627 70574 53218839
Hypokalaemia 23.77 13.26 187 59466 96330 53193083
Cerebellar haemangioma 23.70 13.26 7 59646 72 53289341
Renal impairment 23.68 13.26 167 59486 83151 53206262
Joint stiffness 23.60 13.26 3 59650 30280 53259133
Malaise 23.59 13.26 271 59382 357346 52932067
Loss of personal independence in daily activities 23.50 13.26 26 59627 69789 53219624
Graft versus host disease 23.32 13.26 34 59619 7088 53282325
Hypophosphataemia 23.17 13.26 38 59615 8767 53280646
Irritable bowel syndrome 22.95 13.26 10 59643 43622 53245791
Salmonella sepsis 22.49 13.26 9 59644 242 53289171
Pregnancy 22.47 13.26 4 59649 31437 53257976
Pneumonia pneumococcal 22.10 13.26 18 59635 1942 53287471
Blood pressure systolic increased 22.06 13.26 6 59647 35171 53254242
Intraductal proliferative breast lesion 22.01 13.26 21 59632 2793 53286620
Hyperproteinaemia 22.00 13.26 7 59646 94 53289319
Injury 21.99 13.26 15 59638 50956 53238457
Neuralgia 21.97 13.26 67 59586 23454 53265959
Varicella zoster virus infection 21.73 13.26 20 59633 2543 53286870
Osteonecrosis of jaw 21.69 13.26 89 59564 36057 53253356
Peritonitis viral 21.65 13.26 6 59647 48 53289365
Cardiac failure 21.51 13.26 167 59486 85677 53203736
Compression fracture 21.40 13.26 31 59622 6425 53282988
Nasal congestion 21.28 13.26 17 59636 53270 53236143
Hypothyroidism 21.12 13.26 7 59646 36100 53253313
Blood cholesterol increased 21.04 13.26 17 59636 52972 53236441
Failure to thrive 20.92 13.26 32 59621 6960 53282453
Gait disturbance 20.80 13.26 99 59554 158743 53130670
Seasonal allergy 20.77 13.26 50 59603 15235 53274178
Myalgia 20.68 13.26 78 59575 133413 53156000
Injection site swelling 20.55 13.26 11 59642 42617 53246796
Enterococcal sepsis 20.52 13.26 15 59638 1379 53288034
Toxic skin eruption 20.07 13.26 45 59608 13094 53276319
Blood creatine phosphokinase increased 20.05 13.26 4 59649 28981 53260432
Somnolence 20.00 13.26 108 59545 167626 53121787
Cardiac failure congestive 19.78 13.26 174 59479 92583 53196830
Serotonin syndrome 19.67 13.26 3 59650 26403 53263010
Neurotoxicity 19.58 13.26 49 59604 15300 53274113
Human chorionic gonadotropin increased 19.17 13.26 14 59639 1286 53288127
Wheezing 19.16 13.26 27 59626 65248 53224165
5q minus syndrome 19.11 13.26 8 59645 242 53289171
Transplant 19.03 13.26 11 59642 677 53288736
Disease recurrence 18.94 13.26 59 59594 20887 53268526
Pain in extremity 18.78 13.26 216 59437 284834 53004579
Mucosal inflammation 18.72 13.26 96 59557 42688 53246725
Toxicity to various agents 18.64 13.26 347 59306 219251 53070162
Cardiotoxicity 18.54 13.26 31 59622 7268 53282145
Plasma cells decreased 18.51 13.26 5 59648 36 53289377
VIth nerve paresis 18.50 13.26 6 59647 86 53289327
Hypoalbuminaemia 18.47 13.26 39 59614 10897 53278516
Incorrect dose administered 18.32 13.26 18 59635 51027 53238386
Full blood count increased 18.19 13.26 12 59641 935 53288478
Light chain analysis 17.91 13.26 4 59649 11 53289402
Mucosal erosion 17.90 13.26 14 59639 1425 53287988
Injection site bruising 17.73 13.26 10 59643 37636 53251777
Fungal oesophagitis 17.69 13.26 10 59643 590 53288823
Sleep disorder 17.63 13.26 24 59629 58846 53230567
Rhabdomyolysis 17.55 13.26 14 59639 43909 53245504
Acute myopia 17.45 13.26 6 59647 104 53289309
Impaired healing 17.44 13.26 28 59625 64177 53225236
Infection reactivation 17.34 13.26 12 59641 1012 53288401
Monoclonal immunoglobulin increased 17.29 13.26 6 59647 107 53289306
Ileus 17.28 13.26 46 59607 14909 53274504
Cough 17.18 13.26 194 59459 256699 53032714
Drug intolerance 17.17 13.26 147 59506 205346 53084067
Drug withdrawal syndrome 17.16 13.26 5 59648 28017 53261396
Sleep apnoea syndrome 17.15 13.26 4 59649 25998 53263415
Bacteraemia 17.13 13.26 47 59606 15502 53273911
Death 16.99 13.26 521 59132 356711 52932702
Sedation 16.93 13.26 6 59647 29669 53259744
Meningitis cryptococcal 16.84 13.26 13 59640 1298 53288115
Paraesthesia 16.76 13.26 217 59436 127298 53162115
Coma 16.73 13.26 27 59626 61756 53227657
Aggression 16.68 13.26 3 59650 23400 53266013
Acute myeloid leukaemia 16.54 13.26 49 59604 16883 53272530
Tooth disorder 16.53 13.26 64 59589 25248 53264165
Infection in an immunocompromised host 16.47 13.26 9 59644 497 53288916
Human herpesvirus 8 infection 16.39 13.26 7 59646 223 53289190
Hypoglossal nerve paresis 16.38 13.26 6 59647 126 53289287
Multiple allergies 16.37 13.26 32 59621 8463 53280950
Pneumonia influenzal 16.33 13.26 14 59639 1621 53287792
Contusion 16.32 13.26 66 59587 110666 53178747
Pulmonary arterial hypertension 16.32 13.26 5 59648 27117 53262296
Myeloma cast nephropathy 16.29 13.26 6 59647 128 53289285
Dysarthria 16.12 13.26 13 59640 40555 53248858
Superficial spreading melanoma stage unspecified 16.12 13.26 6 59647 132 53289281
Chronic graft versus host disease in skin 16.10 13.26 10 59643 702 53288711
Lactic acidosis 16.02 13.26 11 59642 37242 53252171
Hypotension 15.89 13.26 384 59269 253692 53035721
Nocardiosis 15.87 13.26 15 59638 1972 53287441
Diarrhoea haemorrhagic 15.62 13.26 31 59622 8289 53281124
Hyperamylasaemia 15.62 13.26 8 59645 387 53289026
Chest discomfort 15.60 13.26 58 59595 99637 53189776
Respiratory tract infection 15.56 13.26 76 59577 33148 53256265
Blood immunoglobulin A increased 15.54 13.26 8 59645 391 53289022
Pseudomyopia 15.46 13.26 5 59648 71 53289342
Asthma 15.41 13.26 66 59587 108906 53180507
Injection site haemorrhage 15.34 13.26 3 59650 22048 53267365
JC virus CSF test positive 15.29 13.26 4 59649 25 53289388
Duodenal stenosis 15.04 13.26 9 59644 591 53288822
Oncologic complication 15.01 13.26 6 59647 161 53289252
Clavicle fracture 14.94 13.26 18 59635 3120 53286293
Osteoporosis 14.88 13.26 18 59635 46442 53242971
Cardiac failure acute 14.86 13.26 32 59621 9060 53280353
Pulmonary oedema 14.86 13.26 107 59546 53616 53235797
Sensory level abnormal 14.84 13.26 6 59647 166 53289247
Underdose 14.82 13.26 3 59650 21519 53267894
Spinal compression fracture 14.71 13.26 41 59612 13649 53275764
Hyperhidrosis 14.70 13.26 57 59596 96736 53192677
Paraproteinaemia 14.57 13.26 6 59647 174 53289239
Haemorrhoidal haemorrhage 14.52 13.26 20 59633 3958 53285455
Spinal fracture 14.51 13.26 46 59607 16439 53272974
Skin exfoliation 14.44 13.26 79 59574 36004 53253409
Staphylococcal bacteraemia 14.34 13.26 23 59630 5210 53284203
Dyspnoea 14.10 13.26 525 59128 585707 52703706
Type 2 diabetes mellitus 14.09 13.26 9 59644 31661 53257752
Ill-defined disorder 13.97 13.26 21 59632 49423 53239990
Acute kidney injury 13.91 13.26 377 59276 253491 53035922
Therapy cessation 13.85 13.26 7 59646 28018 53261395
Blepharitis 13.84 13.26 15 59638 2319 53287094
Urticaria 13.82 13.26 92 59561 135793 53153620
Clostridium difficile colitis 13.76 13.26 51 59602 19714 53269699
Back pain 13.74 13.26 351 59302 233896 53055517
Performance status decreased 13.61 13.26 18 59635 3425 53285988
Crying 13.58 13.26 4 59649 22258 53267155
Blood immunoglobulin A decreased 13.54 13.26 7 59646 345 53289068
Atelectasis 13.52 13.26 51 59602 19875 53269538
Precursor B-lymphoblastic lymphoma 13.50 13.26 3 59650 8 53289405
Pulmonary embolism 13.50 13.26 191 59462 114251 53175162
Rash pruritic 13.49 13.26 99 59554 49911 53239502
Hepatitis B 13.36 13.26 19 59634 3873 53285540

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Plasma cell myeloma 5325.22 13.05 2552 67641 55062 32388271
Neuropathy peripheral 2282.39 13.05 1634 68559 75348 32367985
Plasma cell myeloma recurrent 557.45 13.05 235 69958 3642 32439691
Thrombocytopenia 413.97 13.05 957 69236 147342 32295991
Polyneuropathy 397.64 13.05 284 69909 12931 32430402
Platelet count decreased 375.58 13.05 789 69404 113802 32329531
Disease progression 315.09 13.05 624 69569 86238 32357095
Plasmacytoma 300.26 13.05 148 70045 3345 32439988
Drug interaction 264.94 13.05 72 70121 218113 32225220
Pneumonia 255.58 13.05 1468 68725 353784 32089549
Unevaluable event 211.85 13.05 309 69884 33277 32410056
Completed suicide 184.42 13.05 3 70190 92514 32350819
Plasma cell leukaemia 179.84 13.05 70 70123 871 32442462
Drug abuse 158.27 13.05 3 70190 80240 32363093
Tumour lysis syndrome 155.45 13.05 174 70019 14373 32428960
Orthostatic hypotension 148.84 13.05 227 69966 25423 32417910
Herpes zoster 145.38 13.05 255 69938 32086 32411247
Amyloidosis 126.54 13.05 72 70121 2194 32441139
Constipation 124.92 13.05 572 69621 125801 32317532
White blood cell count decreased 123.50 13.05 455 69738 90743 32352590
Peripheral sensory neuropathy 120.22 13.05 105 70088 6409 32436924
Diarrhoea 115.15 13.05 1247 68946 363555 32079778
Overdose 110.74 13.05 26 70167 87051 32356282
Product use issue 102.69 13.05 298 69895 52479 32390854
Fatigue 99.79 13.05 1175 69018 349526 32093807
Deep vein thrombosis 97.48 13.05 331 69862 63382 32379951
Headache 94.32 13.05 175 70018 196022 32247311
Autonomic neuropathy 93.68 13.05 44 70149 890 32442443
Neutropenia 92.76 13.05 574 69619 141601 32301732
Hypercalcaemia 90.71 13.05 130 70063 13764 32429569
Light chain analysis increased 88.25 13.05 45 70148 1095 32442238
Product use in unapproved indication 87.77 13.05 397 69796 86807 32356526
Rhabdomyolysis 85.68 13.05 20 70173 67245 32376088
Full blood count decreased 78.85 13.05 136 70057 16874 32426459
Ileus paralytic 75.17 13.05 78 70115 5908 32437425
Psoriasis 74.05 13.05 7 70186 46116 32397217
Thrombosis 72.88 13.05 241 69952 45513 32397820
Rash 69.66 13.05 724 69469 208609 32234724
Pancytopenia 68.91 13.05 383 69810 90852 32352481
Off label use 67.90 13.05 981 69212 305339 32137994
Blood creatine phosphokinase increased 67.73 13.05 9 70184 45467 32397866
Hypertension 63.70 13.05 117 70076 131633 32311700
Primary amyloidosis 63.46 13.05 20 70173 125 32443208
Depression 61.84 13.05 71 70122 96989 32346344
Therapy partial responder 61.48 13.05 64 70129 4866 32438467
Osteonecrosis of jaw 60.26 13.05 130 70063 19036 32424297
Myelodysplastic syndrome 58.57 13.05 132 70061 19906 32423427
Arthralgia 56.05 13.05 151 70042 148297 32295036
Chalazion 55.39 13.05 17 70176 96 32443237
Adverse drug reaction 55.13 13.05 151 70042 25710 32417623
Spinal compression fracture 54.73 13.05 70 70123 6646 32436687
Inappropriate schedule of product administration 53.83 13.05 16 70177 45809 32397524
Aggression 53.67 13.05 10 70183 39379 32403954
Pyrexia 52.71 13.05 976 69217 318992 32124341
Seizure 50.38 13.05 92 70101 103762 32339571
Hypoaesthesia 49.51 13.05 253 69940 58100 32385233
Anxiety 49.34 13.05 82 70111 95923 32347410
Abdominal pain 49.30 13.05 162 70031 149367 32293966
Protein total increased 48.91 13.05 40 70153 2229 32441104
Atrial fibrillation 48.86 13.05 424 69769 116280 32327053
Cardiac amyloidosis 48.66 13.05 29 70164 965 32442368
Cytopenia 47.34 13.05 81 70112 9983 32433350
Drug hypersensitivity 46.41 13.05 54 70139 73346 32369987
Neuralgia 46.41 13.05 88 70105 11747 32431586
Laboratory test abnormal 46.35 13.05 117 70076 18970 32424363
Plasma cell myeloma refractory 45.63 13.05 13 70180 54 32443279
Suicidal ideation 45.27 13.05 13 70180 38070 32405263
Condition aggravated 45.12 13.05 178 70015 155483 32287850
Spinal cord compression 44.50 13.05 48 70145 3801 32439532
Blood pressure increased 44.38 13.05 64 70129 79290 32364043
Stem cell transplant 43.32 13.05 37 70156 2190 32441143
Infection 43.17 13.05 322 69871 84393 32358940
Wrong technique in product usage process 41.62 13.05 12 70181 35047 32408286
Hypoglycaemia 41.32 13.05 34 70159 54348 32388985
Sepsis 39.65 13.05 520 69673 158314 32285019
Asthma 39.51 13.05 23 70170 44042 32399291
Compression fracture 39.12 13.05 40 70153 2977 32440356
Ageusia 39.11 13.05 73 70120 9629 32433704
Peripheral sensorimotor neuropathy 38.39 13.05 29 70164 1438 32441895
Paraesthesia 37.73 13.05 237 69956 58707 32384626
Hallucination 37.44 13.05 35 70158 52584 32390749
Monoclonal immunoglobulin present 37.37 13.05 24 70169 914 32442419
Pathological fracture 37.29 13.05 46 70147 4210 32439123
Neutrophil count decreased 36.96 13.05 200 69993 46939 32396394
Metapneumovirus infection 36.93 13.05 21 70172 639 32442694
Hyperviscosity syndrome 36.56 13.05 15 70178 216 32443117
Bradycardia 35.95 13.05 62 70131 71500 32371833
Osteolysis 35.37 13.05 30 70163 1759 32441574
B precursor type acute leukaemia 34.75 13.05 13 70180 144 32443189
Hyperkalaemia 33.62 13.05 62 70131 69688 32373645
Rash pruritic 33.41 13.05 123 70070 24488 32418845
Septic shock 33.33 13.05 259 69934 68730 32374603
Haematochezia 33.03 13.05 22 70171 39186 32404147
Disseminated varicella zoster virus infection 32.62 13.05 23 70170 1024 32442309
Stress 32.48 13.05 6 70187 23776 32419557
Squamous cell carcinoma of skin 32.44 13.05 68 70125 9758 32433575
Hypogammaglobulinaemia 32.12 13.05 52 70141 6124 32437209
Oroantral fistula 31.39 13.05 14 70179 250 32443083
Bone pain 31.34 13.05 106 70087 20238 32423095
Agitation 31.18 13.05 47 70146 57189 32386144
Guillain-Barre syndrome 31.10 13.05 48 70145 5426 32437907
Adenocarcinoma of colon 31.04 13.05 38 70155 3451 32439882
Myocardial infarction 30.20 13.05 154 70039 125522 32317811
Flushing 29.73 13.05 15 70178 31112 32412221
Angioedema 29.72 13.05 21 70172 36268 32407065
Malaise 29.37 13.05 243 69950 176895 32266438
Hiccups 28.71 13.05 65 70128 9830 32433503
Electrocardiogram QT prolonged 28.63 13.05 26 70167 39615 32403718
Pulmonary embolism 28.50 13.05 291 69902 83368 32359965
Asthenia 28.12 13.05 687 69506 235257 32208076
Meningitis pneumococcal 28.03 13.05 11 70182 140 32443193
Peripheral motor neuropathy 27.73 13.05 26 70167 1740 32441593
Blood stem cell harvest failure 27.69 13.05 7 70186 16 32443317
Dehydration 27.62 13.05 411 69782 128547 32314786
Somnolence 27.38 13.05 123 70070 103674 32339659
Respirovirus test positive 27.21 13.05 9 70184 67 32443266
Drug-induced liver injury 27.19 13.05 9 70184 24054 32419279
Ileus 27.07 13.05 87 70106 16178 32427155
Intentional product misuse 26.81 13.05 23 70170 36028 32407305
Bone disorder 26.78 13.05 51 70142 6829 32436504
Erythema 26.70 13.05 91 70102 83014 32360319
Therapy non-responder 26.58 13.05 140 70053 32514 32410819
Colitis ulcerative 26.30 13.05 3 70190 17048 32426285
VIth nerve paralysis 26.29 13.05 18 70175 764 32442569
Diverticular perforation 26.28 13.05 34 70159 3264 32440069
Contraindicated product administered 25.65 13.05 5 70188 19071 32424262
Bone marrow failure 25.19 13.05 131 70062 30273 32413060
Hyperhidrosis 24.90 13.05 75 70118 71093 32372240
Cytomegalovirus infection 24.88 13.05 115 70078 25349 32417984
Bacteraemia 24.67 13.05 89 70104 17544 32425789
Lactic acidosis 24.21 13.05 22 70171 33514 32409819
Mobility decreased 23.85 13.05 16 70177 28393 32414940
Gastric ulcer 23.84 13.05 3 70190 15806 32427527
Renal failure 23.71 13.05 415 69778 134063 32309270
Tooth deposit 23.64 13.05 9 70184 105 32443228
Metabolic acidosis 23.57 13.05 32 70161 40667 32402666
Abnormal behaviour 23.46 13.05 14 70179 26452 32416881
Bacterial infection 23.38 13.05 75 70118 13931 32429402
Performance status decreased 23.38 13.05 36 70157 4062 32439271
Bone lesion 22.92 13.05 30 70163 2913 32440420
Haemoglobin decreased 22.80 13.05 374 69819 119297 32324036
Myalgia 22.80 13.05 94 70099 81136 32362197
H1N1 influenza 22.79 13.05 18 70175 954 32442379
Cytomegalovirus infection reactivation 22.61 13.05 32 70161 3347 32439986
Emotional distress 22.51 13.05 4 70189 16302 32427031
Osteonecrosis 22.50 13.05 83 70110 16539 32426794
Coronary artery disease 22.37 13.05 46 70147 49660 32393673
Gastrointestinal amyloidosis 22.32 13.05 6 70187 19 32443314
Pallor 21.89 13.05 11 70182 22870 32420463
Incorrect dose administered 21.88 13.05 26 70167 35002 32408331
Drug level increased 21.84 13.05 8 70185 20072 32423261
Cerebrovascular accident 21.74 13.05 104 70089 86216 32357117
Jaundice 21.72 13.05 25 70168 34133 32409200
Anaphylactic reaction 21.54 13.05 20 70173 30152 32413181
Basal cell carcinoma 21.54 13.05 85 70108 17483 32425850
Dysarthria 21.44 13.05 24 70169 33177 32410156
Respiratory tract infection 21.43 13.05 84 70109 17221 32426112
Acute myeloid leukaemia 21.31 13.05 90 70103 19084 32424249
Cystitis haemorrhagic 21.26 13.05 39 70154 5075 32438258
Visceral leishmaniasis 21.16 13.05 14 70179 561 32442772
Brief psychotic disorder with marked stressors 20.95 13.05 10 70183 210 32443123
Progressive multifocal leukoencephalopathy 20.65 13.05 56 70137 9475 32433858
Clostridium difficile colitis 20.62 13.05 73 70120 14258 32429075
Hordeolum 20.47 13.05 16 70177 835 32442498
Rectal adenocarcinoma 20.30 13.05 16 70177 845 32442488
Autologous haematopoietic stem cell transplant 20.23 13.05 5 70188 10 32443323
Monoclonal gammopathy 20.20 13.05 11 70182 307 32443026
Rib fracture 20.20 13.05 71 70122 13818 32429515
Chronic inflammatory demyelinating polyradiculoneuropathy 20.14 13.05 15 70178 728 32442605
Febrile neutropenia 20.01 13.05 366 69827 119200 32324133
Blood immunoglobulin A increased 19.76 13.05 11 70182 321 32443012
Drug ineffective 19.67 13.05 655 69538 382822 32060511
Palmar-plantar erythrodysaesthesia syndrome 19.42 13.05 5 70188 15744 32427589
Wheezing 19.39 13.05 31 70162 36843 32406490
Cardiac arrest 19.26 13.05 126 70067 96650 32346683
Neurogenic bladder 19.18 13.05 21 70172 1691 32441642
Injection site pain 19.13 13.05 26 70167 33032 32410301
Disturbance in attention 19.12 13.05 14 70179 23739 32419594
Haematotoxicity 19.09 13.05 44 70149 6732 32436601
Conjunctival irritation 19.08 13.05 8 70185 122 32443211
Accidental overdose 18.95 13.05 9 70184 19330 32424003
Dyskinesia 18.88 13.05 14 70179 23589 32419744
Product quality issue 18.77 13.05 9 70184 19224 32424109
Blood calcium increased 18.77 13.05 30 70163 3495 32439838
Blood immunoglobulin M increased 18.64 13.05 9 70184 194 32443139
Respiratory arrest 18.55 13.05 21 70172 28887 32414446
Parainfluenzae virus infection 18.48 13.05 24 70169 2313 32441020
Hallucination, visual 18.39 13.05 7 70186 17152 32426181
Acute febrile neutrophilic dermatosis 18.37 13.05 18 70175 1273 32442060
Depressed level of consciousness 18.21 13.05 38 70155 40809 32402524
Infusion related reaction 18.18 13.05 164 70029 45435 32397898
Product prescribing error 18.09 13.05 10 70183 19707 32423626
Cholestasis 18.05 13.05 19 70174 27014 32416319
Tachycardia 17.82 13.05 99 70094 78989 32364344
Spinal fracture 17.67 13.05 44 70149 7072 32436261
Peripheral swelling 17.53 13.05 225 69968 68120 32375213
Acute lymphocytic leukaemia 17.45 13.05 29 70164 3489 32439844
Blood pressure fluctuation 17.36 13.05 11 70182 20124 32423209
Adenovirus infection 17.24 13.05 34 70159 4670 32438663
Taste disorder 17.21 13.05 34 70159 4677 32438656
Hyperlipidaemia 17.16 13.05 5 70188 14506 32428827
Enterococcal infection 17.14 13.05 51 70142 9096 32434237
Demyelinating polyneuropathy 17.08 13.05 17 70176 1225 32442108
Blood immunoglobulin G increased 17.08 13.05 15 70178 922 32442411
Neutropenic sepsis 16.84 13.05 63 70130 12636 32430697
Vomiting 16.79 13.05 384 69809 235173 32208160
Injury 16.78 13.05 14 70179 22231 32421102
Pleuritic pain 16.77 13.05 27 70166 3165 32440168
Blood lactate dehydrogenase increased 16.73 13.05 92 70101 21713 32421620
Respiratory depression 16.67 13.05 4 70189 13207 32430126
Gastrooesophageal reflux disease 16.62 13.05 31 70162 34707 32408626
Type 2 diabetes mellitus 16.58 13.05 6 70187 15166 32428167
Full blood count increased 16.34 13.05 14 70179 832 32442501
Renal amyloidosis 16.32 13.05 6 70187 63 32443270
Musculoskeletal stiffness 16.29 13.05 38 70155 39226 32404107
Haematuria 16.18 13.05 52 70141 48309 32395024
Toxicity to various agents 15.97 13.05 500 69693 177541 32265792
Sopor 15.96 13.05 3 70190 11746 32431587
Morganella infection 15.92 13.05 11 70182 474 32442859
Pleural effusion 15.83 13.05 249 69944 78743 32364590
Anaemia 15.81 13.05 611 69582 223013 32220320
Ascites 15.81 13.05 40 70153 40151 32403182
Depressed mood 15.78 13.05 10 70183 18290 32425043
Melaena 15.66 13.05 32 70161 34633 32408700
Hepatocellular injury 15.59 13.05 19 70174 25299 32418034
Genital erythema 15.49 13.05 8 70185 200 32443133
Hepatitis 15.43 13.05 17 70176 23676 32419657
Escherichia sepsis 15.43 13.05 31 70162 4317 32439016
Nephrolithiasis 15.34 13.05 22 70171 27332 32416001
Autonomic nervous system imbalance 15.32 13.05 23 70170 2537 32440796
Laryngeal cancer metastatic 15.25 13.05 6 70187 77 32443256
Diabetic ketoacidosis 15.18 13.05 10 70183 17922 32425411
Haemorrhagic fever 15.14 13.05 5 70188 37 32443296
Light chain analysis decreased 14.91 13.05 5 70188 39 32443294
Coma 14.83 13.05 45 70148 42567 32400766
VIth nerve paresis 14.80 13.05 5 70188 40 32443293
Refractory anaemia with an excess of blasts 14.76 13.05 10 70183 417 32442916
Acute myocardial infarction 14.74 13.05 65 70128 55084 32388249
Blepharitis 14.72 13.05 15 70178 1112 32442221
Alanine aminotransferase increased 14.70 13.05 104 70089 78375 32364958
Loss of personal independence in daily activities 14.64 13.05 22 70171 26811 32416522
Aphasia 14.64 13.05 14 70179 20814 32422519
Spinal pain 14.63 13.05 33 70160 4978 32438355
Plasmablastic lymphoma 14.59 13.05 9 70184 319 32443014
Body height decreased 14.50 13.05 28 70165 3787 32439546
Blood culture positive 14.48 13.05 33 70160 5012 32438321
Refractory cytopenia with multilineage dysplasia 14.45 13.05 7 70186 152 32443181
Obstructive airways disorder 14.37 13.05 4 70189 11957 32431376
Synovitis 14.31 13.05 3 70190 10875 32432458
Hypersensitivity 14.30 13.05 70 70123 57688 32385645
Fat tissue increased 14.29 13.05 10 70183 440 32442893
Pregnancy of partner 14.27 13.05 9 70184 332 32443001
Extrapyramidal disorder 14.25 13.05 4 70189 11891 32431442
Mantle cell lymphoma 14.19 13.05 18 70175 1695 32441638
Serratia sepsis 14.16 13.05 4 70189 16 32443317
Pneumonia mycoplasmal 14.16 13.05 11 70182 569 32442764
Glomerular filtration rate decreased 14.11 13.05 5 70188 12806 32430527
Agranulocytosis 14.06 13.05 18 70175 23459 32419874
Hypercapnic coma 14.04 13.05 7 70186 162 32443171
Blood triglycerides increased 14.02 13.05 7 70186 14612 32428721
Heart rate increased 13.97 13.05 45 70148 41783 32401550
Restlessness 13.96 13.05 20 70173 24861 32418472
Dystonia 13.84 13.05 3 70190 10620 32432713
Cellulitis orbital 13.69 13.05 9 70184 357 32442976
Blastic plasmacytoid dendritic cell neoplasia 13.67 13.05 6 70187 103 32443230
Colitis 13.47 13.05 122 70071 33829 32409504
Blood glucose increased 13.45 13.05 84 70109 65157 32378176
Glycosylated haemoglobin increased 13.40 13.05 3 70190 10386 32432947
Oesophageal adenocarcinoma 13.36 13.05 13 70180 911 32442422
Seasonal allergy 13.30 13.05 33 70160 5291 32438042
Neurotoxicity 13.23 13.05 66 70127 15004 32428329
Mantle cell lymphoma recurrent 13.22 13.05 10 70183 497 32442836
Hyposmia 13.07 13.05 7 70186 189 32443144
Blood pressure systolic increased 13.05 13.05 11 70182 17385 32425948

Pharmacologic Action:

SourceCodeDescription
ATC L01XG01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Proteasome inhibitors
FDA MoA N0000175075 Proteasome Inhibitors
FDA EPC N0000175604 Proteasome Inhibitor
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:35820 antiprotozoal agent
CHEBI has role CHEBI:37670 protease inhibitors
CHEBI has role CHEBI:52726 proteasome inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Systemic AL amyloidosis indication 23132008
Multiple myeloma indication 109989006 DOID:9538
Mantle cell lymphoma indication 443487006
Orthostatic hypotension contraindication 28651003
Dehydration contraindication 34095006
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Interstitial pneumonia contraindication 64667001
Adult respiratory distress syndrome contraindication 67782005 DOID:11394
Pulmonary hypertension contraindication 70995007 DOID:6432
Diabetes mellitus contraindication 73211009 DOID:9351
Intestinal obstruction contraindication 81060008 DOID:8437
Prolonged QT interval contraindication 111975006
Pneumonia contraindication 233604007 DOID:552
Disease of liver contraindication 235856003 DOID:409
Syncope contraindication 271594007
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006
Neutropenic disorder contraindication 303011007 DOID:1227
Breastfeeding (mother) contraindication 413712001
Posterior reversible encephalopathy syndrome contraindication 450886002
Chemotherapy-Induced Hyperuricemia contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.39 acidic
pKa2 12.09 acidic
pKa3 13.65 acidic
pKa4 2.9 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
3.5MG/VIAL VELCADE TAKEDA PHARMS USA N021602 May 13, 2003 RX INJECTABLE INTRAVENOUS, SUBCUTANEOUS April 8, 2022 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Proteasome subunit beta type-5 Enzyme INHIBITOR Ki 9.26 CHEMBL CHEMBL
Proteasome subunit beta type-8 Enzyme INHIBITOR IC50 8.09 CHEMBL CHEMBL
Proteasome subunit alpha type-1 Enzyme INHIBITOR Ki 9.21 WOMBAT-PK CHEMBL
Proteasome subunit beta type-1 Enzyme INHIBITOR IC50 7.28 CHEMBL CHEMBL
Proteasome subunit beta type-2 Enzyme INHIBITOR IC50 6.23 CHEMBL CHEMBL
Prothrombin Enzyme Ki 4.89 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 5.16 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 5.17 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 5.16 CHEMBL
Cytochrome P450 2C19 Enzyme Ki 4.75 WOMBAT-PK
26S proteasome non-ATPase regulatory subunit 1 Cytosolic other Ki 7.75 WOMBAT-PK
Neutrophil elastase Enzyme Ki 5.64 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 5.34 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 5.36 CHEMBL
Cathepsin G Enzyme Ki 6.20 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 5.48 CHEMBL
Chymase Enzyme IC50 5.92 CHEMBL
Chymotrypsinogen B Enzyme Ki 6.49 CHEMBL
Lysosomal protective protein Enzyme IC50 5.04 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 5.07 CHEMBL
PH and SEC7 domain-containing protein 1 Unclassified Ki 7.75 WOMBAT-PK
Nuclear factor NF-kappa-B complex Transcription factor IC50 8.01 CHEMBL
Proteasome subunit beta type-9 Enzyme IC50 8.52 CHEMBL
Proteasome subunit beta type-10 Enzyme IC50 6.03 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 5.94 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 5.89 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.19 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 5.47 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 5.23 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 5.57 CHEMBL
Beta-carbonic anhydrase 1 Enzyme Ki 5.14 CHEMBL
Alpha-chymotrypsin Enzyme Ki 5.62 CHEMBL
Proteasome subunit beta Enzyme IC50 7.51 IUPHAR
Proteasome subunit beta type-8 Enzyme IC50 7.78 CHEMBL
ATP-dependent Clp protease proteolytic subunit Enzyme IC50 5.28 CHEMBL

External reference:

IDSource
4021393 VUID
N0000148811 NUI
D03150 KEGG_DRUG
C1176309 UMLSCUI
CHEBI:52717 CHEBI
BO2 PDB_CHEM_ID
CHEMBL325041 ChEMBL_ID
DB00188 DRUGBANK_ID
D000069286 MESH_DESCRIPTOR_UI
387447 PUBCHEM_CID
6391 IUPHAR_LIGAND_ID
8331 INN_ID
69G8BD63PP UNII
356733 RXNORM
17263 MMSL
233935 MMSL
46756 MMSL
d04871 MMSL
009985 NDDF
398907002 SNOMEDCT_US
407097007 SNOMEDCT_US
4021393 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bortezomib HUMAN PRESCRIPTION DRUG LABEL 1 43598-865 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3.50 mg INTRAVENOUS NDA 26 sections
VELCADE HUMAN PRESCRIPTION DRUG LABEL 1 63020-049 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3.50 mg INTRAVENOUS NDA 31 sections
Bortezomib HUMAN PRESCRIPTION DRUG LABEL 1 63323-721 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 mg INTRAVENOUS NDA 28 sections